News | February 21, 2022
SEBI approves IPO plans of PharmEasy and Wellness Forever Medicare
The companies plan to use the proceeds to retire debt and expand operations
The companies plan to use the proceeds to retire debt and expand operations
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The Healthcare Technology Report provides market research and insights, business news, investment activity updates and important corporate developments related to the healthcare technology sector
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Subscribe To Our Newsletter & Stay Updated
